1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea is a chemical compound with a complex structure. It's likely a synthetic molecule, and the specific significance of its structure would depend on the context of its research.
**Here's what we can gather from its name and structure:**
* **1-(1,3-benzodioxol-5-yl):** This part indicates a **benzodioxole ring** substituted at the 5-position. Benzodioxoles are common structural motifs found in many natural products and pharmaceuticals, often associated with biological activity.
* **3-(6-methyl-2-pyridinyl):** This part indicates a **pyridinyl ring** substituted at the 2-position and with a methyl group at the 6-position. Pyridine rings are also frequently found in pharmaceuticals and natural products, often contributing to their biological activity.
* **Urea:** This is a functional group known for its ability to form hydrogen bonds. Many urea derivatives have pharmacological properties, including acting as enzyme inhibitors or targeting specific receptors.
**Potential Research Importance:**
Given its structure, 1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea could be of interest for research in several areas:
* **Pharmacology:** This compound might show activity as a drug candidate due to its combination of benzodioxole and pyridinyl rings, which are associated with biological effects. It could be investigated for various therapeutic applications, such as anti-cancer, anti-inflammatory, or anti-microbial effects.
* **Materials Science:** The presence of the urea group suggests this compound could have properties related to polymers or coatings due to its potential for hydrogen bonding.
* **Organic Chemistry:** This compound could be a valuable synthetic building block or intermediate for the development of new molecules with desired properties.
**To understand the specific research importance of this compound, you would need more information:**
* **The research context:** What is the specific research question being investigated?
* **The experimental data:** What are the observed effects of this compound?
* **The specific applications:** What is the potential use of this compound in a particular field?
Without this additional information, it's difficult to pinpoint the exact reason why this compound is being studied.
ID Source | ID |
---|---|
PubMed CID | 6465706 |
CHEMBL ID | 1464737 |
CHEBI ID | 116308 |
Synonym |
---|
HMS2596C12 |
MLS000679398 |
n-1,3-benzodioxol-5-yl-n'-(6-methyl-2-pyridinyl)urea |
smr000297565 |
1-(1,3-benzodioxol-5-yl)-3-(6-methylpyridin-2-yl)urea |
STK469982 |
AKOS003339490 |
CHEMBL1464737 |
HMS3381P07 |
Q27199166 |
1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea |
CHEBI:116308 |
n-(1,3-benzodioxol-5-yl)-n'-(6-methyl-2-pyridyl)urea |
Class | Description |
---|---|
benzodioxoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 2.6855 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.5012 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 7.4993 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.5893 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
glucocerebrosidase | Homo sapiens (human) | Potency | 12.5893 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 1.7783 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 11.5821 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 14.1254 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 29.0929 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.2387 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
snurportin-1 | Homo sapiens (human) | Potency | 29.0929 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 29.0929 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 7.0795 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 7.0795 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 7.0795 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |